Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab plus talazoparib in BRCA- or ATM-mutant advanced solid tumors
2018-000345-39Phase 2Unknown
- Sponsor
- Pfizer
- Start
- Jul 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab and talazoparib in Non-hematologic malignancy, sponsored by Pfizer. Primary endpoint: Confirmed objective response. Status: unknown.
02
Drugs
avelumabtalazoparib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2018-000345-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000345-39.